이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발/난치성 DLBCL 환자에서 HMPL-760과 R-GemOx 병용 요법 대 위약과 R-GemOx 병용 요법의 3상 임상시험

2026년 11월 9일 업데이트: Hutchmed

재발성/난치성 미만성 대형 B세포 림프종(DLBCL) 환자에서 HMPL-760과 R-GemOx 병용 요법 대 위약과 R-GemOx 병용 요법의 효능, 안전성 및 약동학을 평가하기 위한 3상 무작위 배정, 이중 맹검, 양성 대조군 임상시험

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

연구 유형

중재적

등록 (추정된)

240

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Baoding, 중국
        • 모병
        • Baoding NO.1 Central Hospital
        • 연락하다:
        • 수석 연구원:
          • Haiying Yao
      • Beijing, 중국
        • 모병
        • Beijing GoBroad Hospital
        • 수석 연구원:
          • Kai Hu
        • 연락하다:
      • Beijing, 중국
        • 모병
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • 수석 연구원:
          • Liang Wang
        • 연락하다:
      • Bengbu, 중국
        • 모병
        • The First Affiliated Hospital of Bengbu Medical College
        • 연락하다:
        • 수석 연구원:
          • Yanli Yang
      • Changchun, 중국
        • 모병
        • The First Hospital of Jilin University
        • 수석 연구원:
          • Ou Bai
        • 연락하다:
      • Changsha, 중국
        • 모병
        • Hunan Cancer Hospital
        • 수석 연구원:
          • Hui Zhou
        • 연락하다:
      • Changsha, 중국
        • 모병
        • The Second Xiangya Hospital of Central South University
        • 수석 연구원:
          • Hongling Peng
        • 연락하다:
      • Changsha, 중국
        • 모병
        • People's Hospital of Hunan Province
        • 연락하다:
        • 수석 연구원:
          • Can Liu
      • Chengdu, 중국
        • 모병
        • West China Hospital of Sichuan University
        • 수석 연구원:
          • Liqun Zou
        • 연락하다:
      • Chengdu, 중국
        • 모병
        • Sichuan Provincial People's Hospital
        • 연락하다:
        • 수석 연구원:
          • Xiaobing Huang
      • Chongqing, 중국
        • 모병
        • The First Affiliated Hospital of Chongqing Medical University
        • 수석 연구원:
          • Xin Wang
        • 연락하다:
      • Chongqing, 중국
        • 모병
        • Chongqing University Cancer Hospital
        • 수석 연구원:
          • Yao Liu
        • 연락하다:
      • Fujian, 중국
        • 모병
        • Quanzhou First Hospital.Fujian
        • 연락하다:
        • 수석 연구원:
          • Xiongpeng Zhu
      • Fuzhou, 중국
        • 모병
        • Fujian Medical University Union Hospital
        • 수석 연구원:
          • Jianzhen Shen
        • 연락하다:
      • Guangzhou, 중국
        • 모병
        • Sun Yat-sen University Cancer Center
        • 수석 연구원:
          • Zhiming Li
        • 연락하다:
      • Guangzhou, 중국
        • 모병
        • Guangdong Provincial People's Hospital
        • 연락하다:
        • 수석 연구원:
          • Xiaojuan Wei
      • Guangzhou, 중국
        • 모병
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • 수석 연구원:
          • Yuhua Li
        • 연락하다:
      • Guiyang, 중국
        • 모병
        • The Affiliated Hospital of Guizhou Medical University
        • 수석 연구원:
          • Yan Zhang
        • 연락하다:
      • Hangzhou, 중국
        • 모병
        • Zhejiang Cancer Hospital
        • 수석 연구원:
          • Haiyan Yang
        • 연락하다:
      • Hangzhou, 중국
        • 모병
        • The First Affiliated Hospital, Zhejiang University
        • 수석 연구원:
          • Zhen Cai
        • 연락하다:
      • Harbin, 중국
        • 모병
        • Harbin Medical University Cancer Hospital
        • 연락하다:
        • 수석 연구원:
          • Qingyuan Zhang
      • Hefei, 중국
        • 모병
        • The Second Affiliated Hospital of Anhui Medical University
        • 연락하다:
        • 수석 연구원:
          • Zhimin Zhai
      • Jinan, 중국
        • 모병
        • Qilu Hospital of Shandong University
        • 연락하다:
        • 수석 연구원:
          • Shuqian Xu
      • Jinan, 중국
        • 모병
        • Shandong Cancer Hospital & Institute
        • 수석 연구원:
          • Zengjun Li
        • 연락하다:
      • Kunming, 중국
        • 아직 모집하지 않음
        • The First Affiliated Hospital of Kunming Medical University
        • 연락하다:
        • 수석 연구원:
          • Mingxia Shi
      • Nanchang, 중국
        • 모병
        • Jiangxi Cancer Hospital
        • 수석 연구원:
          • Yan Huang
        • 연락하다:
      • Nanjing, 중국
        • 모병
        • Jiangsu Cancer Hospital
        • 수석 연구원:
          • Yan Zhang
        • 연락하다:
      • Nanjing, 중국
        • 모병
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • 연락하다:
        • 수석 연구원:
          • Jingyan Xu
      • Nanning, 중국
        • 모병
        • The First Affiliated Hospital of Guangxi Medical University
        • 수석 연구원:
          • Zhigang Peng
        • 연락하다:
      • Qingdao, 중국
        • 모병
        • The Affiliated Hospital of Qingdao University
        • 연락하다:
        • 수석 연구원:
          • Xia Zhao
      • Shanghai, 중국
        • 모병
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • 수석 연구원:
          • Weili Zhao
        • 연락하다:
      • Shanghai, 중국
        • 모병
        • Tongji Hospital of Tongji University
        • 연락하다:
        • 수석 연구원:
          • Ping Li
      • Shanghai, 중국
        • 아직 모집하지 않음
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • 수석 연구원:
          • Ligen Liu
        • 연락하다:
      • Shenyang, 중국
        • 모병
        • Shengjing Hospital of China Medical University
        • 수석 연구원:
          • Wei Yang
        • 연락하다:
      • Shenzhen, 중국
        • 모병
        • Shenzhen people's hospital
        • 수석 연구원:
          • Jihao Zhou
        • 연락하다:
      • Taiyuan, 중국
        • 모병
        • Shanxi Provincial Cancer Hospital
        • 수석 연구원:
          • Liping Su
        • 연락하다:
      • Tangshan, 중국
        • 모병
        • North China University of Science and Technology Affiliated Hospital
        • 연락하다:
        • 수석 연구원:
          • Zhenyu Yan
      • Tianjin, 중국
        • 모병
        • Tianjin Medical University Cancer Institute & Hospital
        • 수석 연구원:
          • Zhengzi Qian
        • 연락하다:
          • Zhengzi Qian
          • 전화번호: 13702031222
          • 이메일: qzz@163.com
      • Tianjin, 중국
        • 모병
        • Tianjin People's Hospital
        • 연락하다:
        • 수석 연구원:
          • Xingli Zhao
      • Tianjin, 중국
        • 모병
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • 수석 연구원:
          • Dehui Zou
        • 연락하다:
      • Wenzhou, 중국
        • 모병
        • The First Affiliated Hospital of WMU
        • 연락하다:
        • 수석 연구원:
          • Songfu Jiang
      • Wuhan, 중국
        • 모병
        • Hubei Cancer Hospital
        • 수석 연구원:
          • Huijing Wu
        • 연락하다:
      • Wuhan, 중국
        • 모병
        • Wuhan Union Hospital of China
        • 수석 연구원:
          • Liling Zhang
        • 연락하다:
      • Xi'an, 중국
        • 모병
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • 수석 연구원:
          • Pengcheng He
        • 연락하다:
      • Xi'an, 중국
        • 모병
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • 수석 연구원:
          • Jie Liu
        • 연락하다:
      • Xiamen, 중국
        • 아직 모집하지 않음
        • The First Affiliated Hospital of Xiamen University
        • 수석 연구원:
          • Bing Xu
        • 연락하다:
      • Xuzhou, 중국
        • 모병
        • The Affiliated Hospital of Xuzhou Medical University
        • 연락하다:
        • 수석 연구원:
          • Wei Sang
      • Zhengzhou, 중국
        • 모병
        • Henan Cancer Hospital
        • 수석 연구원:
          • Keshu Zhou
        • 연락하다:
      • Zhengzhou, 중국
        • 모병
        • The First Affiliated Hospital of Zhengzhou University
        • 연락하다:
        • 수석 연구원:
          • Xudong Zhang
      • Ürümqi, 중국
        • 모병
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • 수석 연구원:
          • Yan Li
        • 연락하다:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국
        • 모병
        • Fudan University Shanghai Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Fangfang Lv

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

다른 이름들:
  • 주사용 젬시타빈 염산염
  • 리툭시맙 주사
  • 옥살리플라틴 주사제
위약 비교기: The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

다른 이름들:
  • 주사용 젬시타빈 염산염
  • 리툭시맙 주사
  • 옥살리플라틴 주사제

Patients will receive HMPL-760 placebo once daily (QD) orally.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free survival (PFS)
기간: Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
기간: Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
기간: Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
기간: Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
기간: Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
기간: Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

2차 결과 측정

결과 측정
측정값 설명
기간
Independent review committee (IRC)-assessed PFS
기간: Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
기간: Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
기간: Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
기간: Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
기간: Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
기간: Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
기간: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
기간: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

기타 결과 측정

결과 측정
측정값 설명
기간
Biomarker assessment
기간: Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
기간: Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
기간: Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
기간: Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
기간: Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
기간: Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
기간: Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Weili Zhao, Ruijin Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 20일

기본 완료 (추정된)

2028년 4월 30일

연구 완료 (추정된)

2028년 12월 30일

연구 등록 날짜

최초 제출

2026년 1월 28일

QC 기준을 충족하는 최초 제출

2026년 2월 6일

처음 게시됨 (실제)

2026년 2월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .